GH Research (NASDAQ:GHRS) Shares Up 6.8%

GH Research PLC (NASDAQ:GHRS - Get Free Report) shares were up 6.8% during trading on Monday . The company traded as high as $11.79 and last traded at $11.78. Approximately 53,825 shares were traded during mid-day trading, a decline of 60% from the average daily volume of 135,350 shares. The stock had previously closed at $11.03.

Analyst Ratings Changes

GHRS has been the subject of a number of research analyst reports. JMP Securities decreased their target price on GH Research from $50.00 to $39.00 and set a "market outperform" rating for the company in a research report on Friday, March 1st. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of GH Research in a research report on Monday, March 4th.

GH Research Stock Performance

The stock has a market capitalization of $609.77 million, a price-to-earnings ratio of -17.24 and a beta of 0.84. The business has a 50-day moving average of $9.79 and a 200-day moving average of $7.82.

GH Research (NASDAQ:GHRS - Get Free Report) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). On average, research analysts predict that GH Research PLC will post -0.96 earnings per share for the current fiscal year.

Institutional Trading of GH Research

A number of hedge funds have recently added to or reduced their stakes in GHRS. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of GH Research by 16.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 92,784 shares of the company's stock valued at $932,000 after buying an additional 12,911 shares during the period. Barclays PLC lifted its holdings in shares of GH Research by 98.2% in the 3rd quarter. Barclays PLC now owns 63,590 shares of the company's stock valued at $640,000 after buying an additional 31,500 shares during the period. PEAK6 Investments LLC lifted its holdings in shares of GH Research by 72.9% in the 3rd quarter. PEAK6 Investments LLC now owns 40,308 shares of the company's stock valued at $405,000 after buying an additional 16,991 shares during the period. Lynx1 Capital Management LP lifted its holdings in shares of GH Research by 13.8% in the 3rd quarter. Lynx1 Capital Management LP now owns 1,103,178 shares of the company's stock valued at $11,087,000 after buying an additional 133,804 shares during the period. Finally, RTW Investments LP lifted its holdings in shares of GH Research by 53.4% in the 3rd quarter. RTW Investments LP now owns 3,327,129 shares of the company's stock valued at $33,438,000 after buying an additional 1,158,172 shares during the period. 56.90% of the stock is owned by institutional investors and hedge funds.

About GH Research

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD.